2025年他泽司他最新价格是多少钱一盒？

Tazerestat is a targeted drug for the treatment of epithelioid sarcoma and follicular lymphoma. Its price, global launch status and drug preparation are crucial to patient treatment choices. This article will conduct a detailed analysis from three aspects: the latest price in 2025, global marketing status and medication preparation, to provide patients with a comprehensive medication reference.

How much is the latest price of a box of tazerestat in 2025?

The market price in 2025 will vary depending on the version, specification and purchase channel. The following is the price reference of the current major versions.

Original drug price

The price of the original version of the drug (200mg*240 tablets) exported to Hong Kong is about US$7,213 per box. This version has stable quality but higher price, and is suitable for patients with long-term treatment needs.

Price of generic drugs

The Lao Lucius version (200mg*56 tablets) is about US$777 per box, and the Lao Big Bear version (200mg*80 tablets) is about US$1,480 per box, providing patients with more choices.

Potential cost changes

Due to exchange rate fluctuations and supply chain effects, prices may fluctuate by 5-10% in 2025. It is recommended to confirm the real-time quotation through formal channels before purchasing and pay attention to possible discount activities.

Drug prices will be adjusted according to market conditions, and patients should make reasonable drug purchase plans based on the treatment cycle and financial ability.

Global marketing status of tazetostat

There are significant differences in the global marketing approval status of tazetostat. Below is the current key listing information.

Main market status

The US FDA approved marketing in January 2020, and the EU EMA approved it in 2021. It is marketed in Japan under the trade name "タズベリク", but it has not yet been approved in mainland China.

Special access channels

Patients in unapproved areas can apply through the "compassionate use" procedure, or purchase it from Hong Kong, Japan and other places through formal channels. Some international pharmacies offer cross-border delivery services, subject to customs regulations.

Future listing prospects

Based on the approval progress, it is expected that it may be approved in mainland China within a few years. The marketing status of drugs will change with the policy adjustments of various countries. It is recommended to regularly check official information or consult professional medical institutions.

Preparation for tazerestat administration

The correct use of tazerestat requires adequate preparation before treatment. The following are the key medication precautions.

Gene testing requirements

Before use for treatment of follicular lymphoma, EZH2 mutation testing is required. Only mutation-positive patients can benefit from treatment, and the cost of testing is about 3,000-5,000 yuan.

Pre-treatment evaluation

Complete complete blood count, liver and kidney function tests and pregnancy test (women of childbearing age). Blood routine and liver function need to be monitored regularly during treatment, and it is recommended to monitor once every 2 weeks.

Dose adjustment protocol

The standard dose is 800 mg twice daily. When adverse reactions of grade 3 or above occur, the dose needs to be reduced to 600 mg or 400 mg twice a day according to the specific situation.

Patients should strictly follow the doctor’s instructions and implement the treatment plan, and inform the doctor promptly if any adverse reactions occur